| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
This often involves evaluating the technical performance of AI systems using diagnostic accuracy metrics (e.g. sensitivity, specificity, diagnostic odds ratio) and assessing their impact on task efficiency and patient health outcomes. |
Introduction and motivation of Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
especially so for the radiology Past studies and reviews concerning medical AI systems in healthcare imaging domains have largely focused on gathering evidence for the utility and safety of AI to demonstrate their feasibility (or lack thereof) for real-world deployment particularly where it concerns diagnostic use case |
Introduction and motivation of Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy refer to Understanding and knowledge of AI technology |
Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The color of the AI machines is NOT listed as influencing the acceptability of AI among healthcare professionals |
3.8. Factors influencing healthcare professional acceptability of AI in
medical imaging domains |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
social influence play in AI acceptability Affects healthcare professionals’ decisions to use AI |
3.8. Factors influencing healthcare professional acceptability of AI in medical imaging domains |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
None of the above |
|
None of the above perceived threat regarding AI usage in healthcare settings |
Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Designing human-centred AI systems essential for increasing AI acceptability among medical professionals |
Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
the 'system usage' category of AI acceptability factors include Factors like value proposition and integration with workflows |
Table 3 (3.8. Factors influencing healthcare professional acceptability of AI in medical imaging domains) of Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
ethicality impact AI acceptability among healthcare professionals Affects views on AI based on compatibility with professional values |
Table 3 (3.8. Factors influencing healthcare professional acceptability of AI in medical imaging domains) of Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
the article emphasize for future AI acceptability studies is Considering user experience and system integration deeply |
Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the loss of midbrain dopamine (DA) |
Introduction of Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
Rats was used to test the STEM-PD product for safety and efficacy |
Method of Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
STEM-PD shows no adverse effects or tumor formation in rats up to 9 months |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
the first-in-human STEM-PD phase I/IIa clinical trial along with the trial design |
SUMMARY of Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM-PD product was manufactured under GMP and quality tested in vitro and in vivo to meet regulatory requirements |
SUMMARY of Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
There were no adverse effects or tumor formation that confirmed the safety of the STEM-PD product in rats |
Conclusion of Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
The cells could not differentiate into dopamine neurons |
|
The cells could not differentiate into dopamine neurons was noted in the efficacy study of STEM-PD in rats |
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson’s disease, STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
Results from flow cytometric release analysis of batch #3 for purity markers FOXA2 and OTX2 |
Figure 1. Manufacturing and quality control of STEM-PD |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
for posteriorizing toward midbrain fates and sonic hedgehog (SHH) for ventralization to obtain VM progenitor cells (Figure 1B; STAR Methods).27 At day 9, fibroblast growth factor 8b (FGF8b) expressed at the midbrain-hindbrain boundary was added to fine-tune patterning toward a caudal VM fate, which we have shown to be associated with successful graft outcome in a preclinical rat model of PD. |
RESULTS-Manufacturing and quality control of STEM-PD
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Development of new cognitive abilities |
|
Development of new cognitive abilities was a key outcome measured in the preclinical trials for efficacy in rats |
RESULTS-STEM-PD clinical trial design |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|